211 related articles for article (PubMed ID: 29362471)
1. Discovery of novel bacterial topoisomerase I inhibitors by use of in silico docking and in vitro assays.
Sandhaus S; Chapagain PP; Tse-Dinh YC
Sci Rep; 2018 Jan; 8(1):1437. PubMed ID: 29362471
[TBL] [Abstract][Full Text] [Related]
2. Machine learning and docking models for Mycobacterium tuberculosis topoisomerase I.
Ekins S; Godbole AA; Kéri G; Orfi L; Pato J; Bhat RS; Verma R; Bradley EK; Nagaraja V
Tuberculosis (Edinb); 2017 Mar; 103():52-60. PubMed ID: 28237034
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Mycobacterium tuberculosis topoisomerase I by m-AMSA, a eukaryotic type II topoisomerase poison.
Godbole AA; Ahmed W; Bhat RS; Bradley EK; Ekins S; Nagaraja V
Biochem Biophys Res Commun; 2014 Apr; 446(4):916-20. PubMed ID: 24642256
[TBL] [Abstract][Full Text] [Related]
4. Small-Molecule Inhibitors Targeting Topoisomerase I as Novel Antituberculosis Agents.
Sandhaus S; Annamalai T; Welmaker G; Houghten RA; Paz C; Garcia PK; Andres A; Narula G; Rodrigues Felix C; Geden S; Netherton M; Gupta R; Rohde KH; Giulianotti MA; Tse-Dinh YC
Antimicrob Agents Chemother; 2016 Jul; 60(7):4028-36. PubMed ID: 27114277
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, evaluation, and CoMFA study of fluoroquinophenoxazine derivatives as bacterial topoisomerase IA inhibitors.
Yu X; Zhang M; Annamalai T; Bansod P; Narula G; Tse-Dinh YC; Sun D
Eur J Med Chem; 2017 Jan; 125():515-527. PubMed ID: 27689733
[TBL] [Abstract][Full Text] [Related]
6. DNA topoisomerase I and DNA gyrase as targets for TB therapy.
Nagaraja V; Godbole AA; Henderson SR; Maxwell A
Drug Discov Today; 2017 Mar; 22(3):510-518. PubMed ID: 27856347
[TBL] [Abstract][Full Text] [Related]
7. Targeting bacterial topoisomerase I to meet the challenge of finding new antibiotics.
Tse-Dinh YC
Future Med Chem; 2015; 7(4):459-71. PubMed ID: 25875873
[TBL] [Abstract][Full Text] [Related]
8. Targeting Mycobacterium tuberculosis topoisomerase I by small-molecule inhibitors.
Godbole AA; Ahmed W; Bhat RS; Bradley EK; Ekins S; Nagaraja V
Antimicrob Agents Chemother; 2015 Mar; 59(3):1549-57. PubMed ID: 25534741
[TBL] [Abstract][Full Text] [Related]
9. Genetic and chemical validation identifies Mycobacterium tuberculosis topoisomerase I as an attractive anti-tubercular target.
Ravishankar S; Ambady A; Awasthy D; Mudugal NV; Menasinakai S; Jatheendranath S; Guptha S; Sharma S; Balakrishnan G; Nandishaiah R; Ramachandran V; Eyermann CJ; Reck F; Rudrapatna S; Sambandamurthy VK; Sharma UK
Tuberculosis (Edinb); 2015 Sep; 95(5):589-98. PubMed ID: 26073894
[TBL] [Abstract][Full Text] [Related]
10. Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis.
Kumar S; Mehra R; Sharma S; Bokolia NP; Raina D; Nargotra A; Singh PP; Khan IA
Tuberculosis (Edinb); 2018 Jan; 108():56-63. PubMed ID: 29523328
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase as target for antibacterial and anticancer drug discovery.
Kathiravan MK; Khilare MM; Nikoomanesh K; Chothe AS; Jain KS
J Enzyme Inhib Med Chem; 2013 Jun; 28(3):419-35. PubMed ID: 22380774
[TBL] [Abstract][Full Text] [Related]
12. Characterization of DNA topoisomerase I from Mycobacterium tuberculosis: DNA cleavage and religation properties and inhibition of its activity.
Godbole AA; Leelaram MN; Bhat AG; Jain P; Nagaraja V
Arch Biochem Biophys; 2012 Dec; 528(2):197-203. PubMed ID: 23085346
[TBL] [Abstract][Full Text] [Related]
13. Identification of potential Mycobacterium tuberculosis topoisomerase I inhibitors: a study against active, dormant and resistant tuberculosis.
Sridevi JP; Suryadevara P; Janupally R; Sridhar J; Soni V; Anantaraju HS; Yogeeswari P; Sriram D
Eur J Pharm Sci; 2015 May; 72():81-92. PubMed ID: 25769524
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of novel bisbenzimidazoles as Escherichia coli topoisomerase IA inhibitors and potential antibacterial agents.
Nimesh H; Sur S; Sinha D; Yadav P; Anand P; Bajaj P; Virdi JS; Tandon V
J Med Chem; 2014 Jun; 57(12):5238-57. PubMed ID: 24856410
[TBL] [Abstract][Full Text] [Related]
15. Mycobacterium tuberculosis gyrase inhibitors as a new class of antitubercular drugs.
Blanco D; Perez-Herran E; Cacho M; Ballell L; Castro J; González Del Río R; Lavandera JL; Remuiñán MJ; Richards C; Rullas J; Vázquez-Muñiz MJ; Woldu E; Zapatero-González MC; Angulo-Barturen I; Mendoza A; Barros D
Antimicrob Agents Chemother; 2015 Apr; 59(4):1868-75. PubMed ID: 25583730
[TBL] [Abstract][Full Text] [Related]
16. Efflux pump inhibition by 11H-pyrido[2,1-b]quinazolin-11-one analogues in mycobacteria.
Sen T; Neog K; Sarma S; Manna P; Deka Boruah HP; Gogoi P; Singh AK
Bioorg Med Chem; 2018 Sep; 26(17):4942-4951. PubMed ID: 30190182
[TBL] [Abstract][Full Text] [Related]
17. Novel compounds targeting bacterial DNA topoisomerase/DNA gyrase.
Ehmann DE; Lahiri SD
Curr Opin Pharmacol; 2014 Oct; 18():76-83. PubMed ID: 25271174
[TBL] [Abstract][Full Text] [Related]
18. In silico discovery and in vitro activity of inhibitors against
Billones JB; Carrillo MC; Organo VG; Sy JB; Clavio NA; Macalino SJ; Emnacen IA; Lee AP; Ko PK; Concepcion GP
Drug Des Devel Ther; 2017; 11():563-574. PubMed ID: 28280303
[TBL] [Abstract][Full Text] [Related]
19. Covalent Complex of DNA and Bacterial Topoisomerase: Implications in Antibacterial Drug Development.
Tiwari PB; Chapagain PP; Seddek A; Annamalai T; Üren A; Tse-Dinh YC
ChemMedChem; 2020 Apr; 15(7):623-631. PubMed ID: 32043806
[TBL] [Abstract][Full Text] [Related]
20. Tricyclic sesquiterpenes from Vetiveria zizanoides (L.) Nash as antimycobacterial agents.
Dwivedi GR; Gupta S; Roy S; Kalani K; Pal A; Thakur JP; Saikia D; Sharma A; Darmwal NS; Darokar MP; Srivastava SK
Chem Biol Drug Des; 2013 Nov; 82(5):587-94. PubMed ID: 23841574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
